Related Experiment Videos
[Chronic hepatitis C in hemodialysis patients]
A C Tan1, R H Kauffmann, R van Leusen
1Afd. Inwendige, Geneeskunde/Maag-, Darm- en Leverziekten, Ziekenhuis Rijnstate, Arnhem.
Nederlands Tijdschrift Voor Geneeskunde
|April 29, 1998
Summary
Hepatitis C virus (HCV) infection is common in dialysis patients, with transmission often occurring in healthcare settings. Antiviral therapies offer a promising option for HCV eradication in these individuals, potentially enabling kidney transplantation.
Area of Science:
- Hepatology
- Virology
- Nephrology
Context:
- Hepatitis C virus (HCV) is a significant cause of chronic liver disease in patients undergoing hemodialysis.
- Key risk factors for HCV infection in this population include duration of dialysis, history of intravenous drug use, and blood transfusions.
- Nosocomial transmission is strongly indicated, necessitating stringent infection control in dialysis units.
Purpose:
- To review the epidemiology and risk factors of HCV infection in hemodialysis patients.
- To evaluate the efficacy of antiviral therapies for HCV in dialysis patients.
- To discuss the implications for patient management, including transplantation.
Summary:
- HCV infection poses a considerable risk to patients on hemodialysis, with transmission often linked to healthcare environments.
- While alpha-interferon shows some efficacy in normalizing transaminases, relapses are frequent.
- Combination antiviral therapy with interferon and ribavirin is emerging as a viable strategy for achieving HCV eradication, paving the way for potential kidney transplantation.
Impact:
- Highlights the critical need for rigorous infection prevention protocols in dialysis centers to curb HCV spread.
- Identifies antiviral therapy as a crucial step towards managing HCV in dialysis patients, improving outcomes and eligibility for transplantation.
- Underscores the evolving therapeutic landscape for chronic viral infections in patients with end-stage renal disease.